Recognizing this timeline can help you manage your expectations
Research shows that GLP-1 receptor agonists like semaglutide typically do not directly interact with common antihypertensive drugs, but weight loss itself can lower blood pressure readings, sometimes requiring medication adjustments
Trends cell Biol
Semaglutide, a more potent GLP-1 agonist, has shown greater weight loss efficacy in general populations and appears promising in preliminary post-bariatric reports, though published data remain sparse
Dysbiosis has been associated with an increased permeability of the gut barrier, a condition that allows endotoxins like LPS to enter the bloodstream, triggering an inflammatory response that can contribute to the progression of CKD (Evenepoel et al., 2023)
Clinical Evidence: GLP-1 Treatment for NAFLD in the UK Emerging clinical evidence suggests GLP-1 receptor agonists may offer therapeutic benefits for patients with NAFLD and NASH, though it is important to note that these medications are not currently licensed specifically for liver disease treatment in the UK
